A newly discovered biomarker associated with a rare metabolic disorder may facilitate better diagnosis and identification of new drugs for clinical trials for the disease. Development of treatments for the neurological symptoms of mucopolysaccharidoses, a family of rare genetic disorders, have been hindered by the lack of objective measures of the extent of central nervous system damage in patients.